The leukocyte integrin LFA-1 (CD1 la/CD 18) plays an important role in lymphocyte recirculation and homotypic interactions. Leukocytes from mice lacking CD11a displayed defects in in vitro homotypic aggregation, in proliferation in mixed lymphocyte reactions, and in response to mitogen. Mutant mice mounted normal cytotoxic T cell (CTL) responses against systemic LCMV and VSV infections and showed normal ex vivo CTL function. However, LFA-l-deficient mice did not reject immunogenic tumors grafted into footpads and did not demonstrate priming response against tumor-specific antigen. Thus CD11a deficiency causes a selective defect in induction of peripheral immune responses whereas responses to systemic infection are normal.
T
he CD11a/CD18 (LFA-1) complex, a cell adhesion molecule essential for cell-mediated cytotoxicity by T-lymphocytes (CTL) and natural killer (NK) cells, plays an important role in host defense (1, 2) . The natural ligands for LFA-1 are ICAM-1, ICAM-2, and ICAM-3, which have been shown to facilitate interactions between T lymphocytes and endothehal tissues, target cells (3, 4) , and antigenpresenting cells (APC) (5, 6) . LFA-1 belongs to the [32- integrin family of adhesion molecules, whose members include MAC-1 (CD11b/CD18), p150,95 (CD11c/CD18), and a putative heterodimer recently described (7) . The CDt lb/CD18 heterodimer has been found to be important for non-specific adhesion of granulocytes and monocytes to endothelial cells, and CD11c/CD18 is reportedly a phagocyte receptor involved in activating cells after binding to bacterial LPS in infected tissues (8) . LFA-1 is thought to be more involved in lymphocyte function (9) and is expressed on lymphocytes, monocytes, granulocytes, and bone marrow cells. A hereditary mutation in the [3-chain (CD18) of the [32-integrin family results in a reduction or lack of a functional CD11a/CD18 (LFA-1), CD11b/CD18, and CD11c/ CD18 heterodimers. Children affected by this lymphocyte adhesion deficiency (LAD) suffer from extreme susceptibility to bacterial and fungal infections (10) (11) (12) (13) .
Whereas a genetic defect in the CD18 gene results in the obliteration of all three [3-2 integrins, CDlla-deficient mice were expected to lack only the LFA-1 family member. Lymphocytes have been shown to require the LFA-1 heterodimer for normal inflammatory responses in vivo (3, 14) . Early studies suggested that LFA-1 probably was crucial to early phase induction of immune responses but was not as important for lymphocyte prohferation (1, 15) . Other results have implicated LFA-1 in recirculation and effector function of primed T lymphocytes. Simultaneous injection of anti-LFA-1 mAb with 2,4 dinitro-fluorobenzene (DNFB) 1 rechallenge blocked DTH responses in DNFBprimed mice, which accompanied a significant reduction in the number of lymphocytes in lymph nodes draining treated skin (16) . In addition, adoptive transfer of LCMV primed lymphocytes treated with anti-LFA-1 mAb blocked the development of DTH responses in naive recipient animals (17) .
Early studies with T-cell lines indicated a possible functional role for LFA-1 in CTL killing of target cells (1, 18, 19) . More recent reports have indicated that tumor-specific CTL against lymphoma cells require LFA-1 expression for normal killing responses (20) , and that virus-induced tumor progression is enhanced in anti-LFA-1 treated mice, reportIAbbreviations used in this paper: DNFB, 2,4 dinitro-fluorobenzene; DTH, delayed-type hypersensitivity; ES, embryonic stem cells; LCMV, lymphocyte choriomeningitis virus; VSV, vesicular stomatitis virus.
edly due not to defects in induction of virus-specific CTL but, rather, as a result of impaired CTL killer function (21) .
The role of LFA-1 in recirculation has been supported by in vitro and in vivo studies. Monoclonal antibody to LFA-1 inhibits in vitro adherence oflymphocytes to lymph node HEV prepared from frozen sections and significantly reduces migration of lymphocytes into lymph nodes and Peyer's patches (22) . The presence or absence of ICAM-1 on HEV has no modulatory effect on lymphocyte attachment and rolling at HEV (4). Lymphocytes expressing high levels of MEL-14 are also less suceptible to the effects of anti-LFA-1 antibody blocking effects on lymphocyte adhesion to HEV (22) . This data on the role of LFA-1 in T cell recirculation raises questions as to the role of the molecule during normal homing responses in vivo.
Splenocytes deficient for ICAM-1 are almost totally defective as stimulators in an MLR (6) . Antibody-blocking studies against ICAMs 1, 2, or 3 showed that dendritic cell APC function for T cells was abrogated by mAbs against ICAM-1 or 2 but not by mAb directed at ICAM-3 (5). Both induction and expansion of lymphocytes has been shown to require LFA-1. Anti-LFA-1 mAb block T cell induction phase to alloantigen but have no effect on proliferation during bulk expansion of alloresponding T cells (23) . These studies and others have revealed that the requirement of LFA-1 by T cells for proliferative responses to antigen can vary depending on the type of APC (24) . Clarification is needed on the role of LFA-1 in the induction antigen-specific CTL.
We have disrupted the murine CDlla gene in embryonic stem cells (ES) cells and generated a mouse strain possessing targeted disruption of both alleles of the CD1 la gene. We observed reduced proliferative responses of enriched T cells in in vitro MLR and after mitogenic stimulation. Unexpectedly, CD 1 la homozygous mutant mice mounted normal T cell responses to lymphocyte choriomeningitis virus (LCMV) and vesicular stomatitis virus (VSV) infections and exhibited normal ex vivo CTL function. However, mutant mice showed defective peripheral priming against tumor cells expressing a tumor-specific antigen and in addition were unable to clear tumors injected into footpads.
Materials and Methods
Preparation of Targeting Construct. To prepare a gene targeting construct, a murine 129 genomic DNA library (Stratagene Inc., La Jolla, CA) was screened using oligonucleotides corresponding to the 5' end of the murine CDlla cDNA. A single lamb& clone containing exons 1 to 6 was isolated. A construct for homologous recombination was prepared by ligation ofa KpnI/SalI fragment (containing the pMClneo polyA neomcin resistance casette) with a 5-kb 5' XbaI/KpnI fragment and a 0.6-kb 3' SalI/ Xbal fragment corresponding to the murine CD11a gene. The long arm of this construct contains exon 1 and part of intron 1, and the short arm contains the 3' portion of exon 6 and part of intron 6. The targeting construct replaces exons 2, 3, 4, 5, and part of exon 6 with the neomycin resistance casette. The first six exons correspond to the signal peptide and the amino-terminal extracellular region of the CD11a gene. A 500-bp HindllI/ BamHI restriction fragment immediately upstream of the region included in the mCD1 la targeting construct was used as a probe in Southern blot analysis for targeted events.
Generation Of ES Cell Line and Mice.
The ES cell line E14 K was electroporated with the CD 1 l a construct, which was linearized at the unique NotI site in the BluescriptlI polylinker at the 3' end. Individual colonies were picked after 10 d of selection in 500 I.tg/ ml of G418 and analyzed by PCR using a primer contained within the neo casette (5' AAC GCA CGG GTG TTG GGT CGT TTG 3') paired with an outside primer (5' ACC AGT CTC TGC TTC TTC TGC AC 3') located in the murine CD11a gene 3' to the targeting construct. Positive clones identified by PCR were confirmed using Southern blotting and hybridizing with a flanking probe. Targeted ES cell clones were injected into day 3.5 C57 BL/6J blastocysts and transferred into the uteri of CD 1 pseudo-pregnant foster mothers, as previously described (25) (26) (27) . Chimeric male and female offsprings were bred to C57 BL/6J, and germ-line transmission of the mutation was documented by PCR and by Southern blotting of tail DNA digested with EcoRI and hybridized with the 5' flanking probe. Mice demonstrating germ line transmission of the targeted allele were then bred to obtain homozygous gene targeted offspring and further backcrosses into C57 BL/6J.
Analysis of Circulating Leukocyte Counts in the Gene-targeted Mice.
Peripheral blood of anesthetized mice was collected from the retroauricular plexus in EDTA-capillary tubes or by cardiac puncture at the time of death. Whole blood was diluted 1:3 in Hanks BBS and total white blood cell counts determined on a hemocytometer. The absolute numbers of each leukocyte population were calculated by multiplying total white blood cell counts by differentials. Blood smears were prepared and stained with Leukostat (Sigma Chem. Co., St. Louis, MO) to count differentials.
Flow Cytometry of Gene-targeted Mice. Cell suspensions fi'om thymus, spleen, lymph nodes, and bone marrow of 6-12-wk-old mice were prepared free from red blood cells. For two-and three-color flow cytometry, 5 • 10 s cells in 100 p,1 were stained with antibodies directly conjugated with FITC or PE: antiCD11a (clone M17/4; PharMingen, San Diego, CA), anti-CD4 (clone YTS 191.1.2; Cedarlane Labs. Ltd., Hornby, ON), anti-CD8 (clone YTS 169.4; Cedarlane Labs.), anti CD18 (clone C71/16), anti CDllb/Mac-1 (clone M1/70), anti-CD3 (clone145 2Cll), anti-B220 (clone RA3-6B2), or anti-GR1 (clone R.B6-8C5; all PharMingen). Cells were incubated at 4~ for 30 min, washed three times, and fixed in PBS/1% paraformaldehyde before analysis on a FACScan | instrument (Becton-Dickinson, Mountain View, CA). FACS | analysis was performed with Lysis II (Becton-Dickinson). Windows for analysis of granulocytes and lymphocytes were set using side scatter and forward scatter.
Contact Hypersensitivity. Contact hypersensitivity was elicited in mice by using DNFB. In brief, 6-8-wk-old mice were immunized on the shaved abdomen with 50 p~l 0.5% DNFB in 4:1 acetone/olive oil at day 0 and day 1. At day 5 these mice were challenged with 10 }xl 0.2% DNFB in 4:1 acetone/olive oil on the inner and outer side of one ear. Ear thickness was measured 24 h after reexposition and compared with the untreated ear.
Thioglycollate-induced Peritonitis. Aged and sex-matched mice were injected i.p. with 1.5 ml 4% thioglycollate on d 0. At +4, +24, and +72 h mice were injected i.p. with 8 ml of PBS (without Ca ++ and Mg ++, 2 mM EDTA, 50 b~m/rnl heparin), their abdomens were massaged and 7 ml oflavage fluid was withdrawn. Peritoneal lavage cells were washed 3• in PBS without Ca ++ and Mg ++ and resuspended in 1 ml of same. Total and differential counts were performed after staining with Turk's solution.
In Vitro Proliferation Assay. Lymph node (LN) cells from +/+, +/-and -/-mice were harvested and 105 cells were stimulated hamster anti mouse CD3 mAb (clone 145 2C11; PharMingen) (10 ~g/ml) in HL-1 media (Hycor Biomedical, Irvine, CA) containing 2% FCS using 96 well round bottom plates. Cells were pulsed overnight with [3H]thymidine after 24, 48, or 72 h. For cross-linking antibody stimulation 96-well flat bottom plates were used and preincubated with rabbit anti-hamster IgG the night before. Cells were pulsed overnight with [3H]thymidine after 48 h. Proliferation was measured by [3H]thymidine incorporation using Matrix 96-Beta-counter. 
Mixed Lymphocyte Reaction (MLR)
.
HomotypicAggregation of Splenocytes. Spleen suspension from +/-
and -/-mice were prepared according to standard procedures by straining spleens through wire mesh. Cells were washed twice and resuspended in DMEM, 5% FCS, Glutamine (200 mM) and b2-ME (10 -6 M). Then 103-105 cells per well (1 ml) were added to 24-well plates. Cells were incubated for 24 h in the presence of 100 ng/m_l PMA. Cell were observed using light microscopy and aggregation was determAned as either present or absent. Fan'mary Ex Vivo CTL Assay Using Macrophage Targets. LCMVspecific CTL were derived as above and ex vivo CTL function was determined using targets derived from -/-mutant mice.
Viruses. VSV grown in BHK cells was kindly provided by
Target cells were obtained by injecting mice with 1 ml thioglycollate at day -5 and harvesting macrophages by peritoneal lavage at day -1. Macrophages were seeded into flat-bottom 96-well plates and incubated overnight with IMDM 10% FCS containing SlCr sodium chromate (0.2 mCi/ml). Cells were then pulsed with 10-5 M LCMV-gp peptide. After 2 h, cells were washed twice and spleen cells were added. 5 h later, 70 ml were pipetted off and radioactivity in the supematant determined in a "/-counter. Since cell numbers and S~Cr uptake in individual wells varies, total release of SlCr was determined in each well by lysing cells with 70 bd of HC1 (1 M) and counting radioactivity remaining in the well; counts derived from 70 l.tl supernatant plus remaining counts were taken as 100%.
Assay for Secondary Responses against VSV. Mice were immunized i.v. with VSV (2 • 106 p.f.u., Indiana strain). After 6 d spleen cells were restimulated with specific antigen by adding VSV nuclear protein class-l-binding peptide (50 raM) to bulk cultures as previously described (29) . After 5 d, in vitro culture were harvested and tested for specific cytotoxicity against VSVinfected EL-4 (H-2 b) target cells. Specific lysis was calculated as above.
Tumor Rejection. Heterozygous and homozygous mutant mice [129JSv (H-2 b) • C57BL/6J (H-2B)] were anesthetized and 2 • 105 MC57 (H-2 b) fibrosarcoma-cells (generated from C57BL/6J) were injected into left hind footpads. Footpad swelling was monitored daily or every second day and measured using a springloaded caliper. Footpad swelling is given in percent as compared to uninjected footpad. MC57gp cells were also injected at 2 • 10 s cells into the left-hind footpad of mice and injected mice were monitored in the same way, or screened for CTL induction.
In Vitro Restimulation of Cytotoxic T Cell Activity afier lmmunization with Tumor. MC57-GP is a methylcholantren induced fi-
brosarcoma (originating from C57BL/6 (H-2 b mice) that has been transfected to stably express an LCMV glycoprotein, which contains the immunodominant epitope for CD8+ T cell responses against LCMV infections (described previously in detail [30] ). 2 • 10 s MC57-GP were injected into the left hind footpads of mice, at day 7 spleens were removed and single cell suspensions restimulated in vitro using irradiated (2,000 rad) LCMV-GP peptide-labeled spleen cells. After 5 d cultures were harvested and tested for generation of LCMV-GP-specific CTL activity against EL-4 target cells, which were labeled with LCMV-GP peptide (aa33-41, 50 raM, 2 h at 37~ EL-4 cells incubated without peptide were used as controls for specificity. Specific lysis was calculated as (experimental release -spontaneous release)/(total release -spontaneous release) • 100%.
Results

Disruption of CDI la Gene and Generation of Homozygous
Mutant Mice. Successfully targeted ES cells possessed a 9-kb fragment on Southern blotting compared to the 13-kb wild-type fragment using a probe from the 5' flanking region of the CDlla gene (Fig. 1, C and D) . All confirmed clones were analyzed with the neo probe to ensure single integration events. Targeted ES cell clones were injected into C57/BL/6J blastocysts and male chimeric mice were bred to C57B1/6J mice. Germ line transmission was confirmed by Southern blotting for two of the independently derived ES cell clones. Southern blotting studies from wildtype (+/+), heterozygous (+/-), and homozygous mu- tant ( -/ -) mice were performed to document the presence of mutation. The expected 13-kb wild-type and 9-kb targeted fragments were observed using the H i n d l I I / BamHI flanking probe (Fig. 1 E) . Additional digestions and the use of neo as a probe confirmed the presence of targeted allele. Heterozygous and homozygous mutant animals were born in expected ratio, survived and grew normally, and were fertile. Animals did not demonstrate any obvious phenotype and remained healthy when maintained under specific pathogen-free conditions.
Splenomegaly and Reduced Lymph Node Size in CD 1 la -~-
Mice. Analysis of 6 -w k -o l d mice (n = 6) did not reveal any gross abnormalities in tissue architecture of major organ systems. However, 6 -w k -o l d mutant mice had twofold enlargement of spleen, while lymph nodes were approximately one-fourth normal size, reflecting higher and lower numbers of lymphocytes, respectively (data not shown). An interesting exception of these observations was the finding that mesenteric lymph nodes were of normal size and cellularity.
Lymphocyte Subsets Unaltered in CD I la -/-Mice. Despite differences in size and cellularity of spleen and lymph nodes in mutant mice, surface markers indicated that lymphocyte subset ratios were unchanged in these tissues. Analysis of lymphocyte subsets and peripheral blood leukocytes (PBL) confirmed that B220-, CD3-, and CD11b-posifive ceils were negative for CD11a expression (Figs. 2 and  3 ). In addition, the cell surface expression of CD18 was reduced to levels expected for its presence only in the MAC-1 heterodimer (Fig. 3) . Since thymocyte selection is influenced by thymocyte avidity with stromal cells, which are known to express ICAM-1 (31), the LFA-1 deficiency might be expected to influence thymocyte ontogeny. However, thymocyte cell numbers were normal (data not shown), as were CD4-CD8 profiles (Fig. 4) .
Immunoglobulin Levels Are Normal in CDI la -/-Mice. Ig subclass irregularities can reflect general dysfunction of the immune system (32) . Moreover, since LFA-1 and ICAM-1 can be upregulated on T and B cells (3), it is conceivable that CD11a might play a role in T:B cell cooperation and, perhaps, in Ig class switching. We found mutant mice housed under pathogen-free conditions to have normal serum Ig levels (IgM, IgG1, IgG2, IgG2a, IgG2b, IgG3, and IgA), suggesting normal B cell and cognate T:B interactions. ;. (33) (34) (35) , and can be blocked by anti-LFA-1 mAb (9). Lymphocytes from LAD patients have also been found not to aggregate in response to phorbol-ester activation (34) . To assess leukocyte adhesion in vitro, we incubated spleen cells with PMA for 24 h and monitored for aggregation (33, 36) . Leukocytes from heterozygous mice formed aggregates, indicative ofhomotypic adhesion, whereas leukocytes from mutant mice failed to aggregate in response to PMA (Fig. 5 A) .
CD11a -/-Enriched T Cells Show Reduced Proliferation. Anti-LFA-1 antibody can inhibit T cell proliferative responses to soluble antigens, alloantigens and mitogens (23, 24) . LFA-1 antibodies have been shown to be comitogenic (37) . Proliferation assays were used to test T cell responses in MLR. Responder lymph node cells from CDlla -/-mice (H-2 b) showed reduced proliferative responses to BALB/c (H-2d), B10 BR (H-2k), and BM12 (H-2 bm12) stimulator cells (Fig. 5 B) . In vitro lymphocyte proliferative responses to soluble anti-TCtk-CD3 antibodies were only 10% compared to controls (Fig. 5 D) . These results confirm LFA-1 involvement in T cell activation (38) . Surprisingly, if CD1 la-/-lymphocytes were crosslinked with anti-CD3 antibody fixed to plastic wells, prohferative responses were normal (Fig. 5 C) , although blast cell formation was delayed by several hours (data not shown).
CD11a --/-Mice Have Reduced Thioglycollate-induced Peritonitis.
Peritoneal lavage ofthioglycollate-induced peritonitis showed a reduction in the total number of infiltrating leukocytes derived from -/-mutant mice. Neutrophils and monocytes exhibit different time courses for extravasation in response to inflammatory stimuli. Accordingly, neutrophil infiltration at 4 h and monocyte infiltration at 24 h was reduced compared to heterozygous controls (Fig. 6) .
CD11a -/-CD8+ T Cells Show Normal CTL Effector Function. Since LFA-1 was initially reported as a molecule centrally involved in CTL and NK cell killer function (1, 2, 18, 39, 40), we naturally investigated CTL function in CDlla -/-mutant mice. Mice were injected i.v. with 2 • 103 PFU LCMV at day -8 or 2 • 106 PFU VSV at day -6. Spleens from infected mice were removed and splenocytes incubated with 51Cr-labeled target cells infected with VSV or loaded with LCMV peptide (1033). Contrary to expectations from results of previous reports, splenocytes from CDlla -/-mice were found to mount normal in vivo CTL responses to both VSV (Fig. 7, A and B) and LCMV (Fig. 7 D) . CTL from VSV-infected mutant mice lysed both ICAM-l-positive (EL-4) (Fig. 7 A) and ICAM-1-negative (MC57) VSV-infected targets (Fig. 7 B) (30) .
Ex vivo CTL function was also determined using macrophage target cells derived from thioglycollate-injected CDlla -/-mutant mice. This was intended to assess if compensatory changes in CTL from -/-mice might have masked an obvious defect in CTL responses in vivo. We found no significant difference for CTL-mediated lysis us- (Fig. 7 C) . Specific lysis of non-infected EL-4 cells was below 10% for all effector cells. Spontaneous release was below 20% for both targets.
NK Cytotoxidty Is Markedly Reduced. NK cells from C D 11 a
-/-mice were defective in their ability to kill YAC-1 targets (Fig. 8) , and this inhibition was comparable to reduced killing observed after treatment with anti-CDlla mAb (41, 42) .
Delayed-type Hypersensitivity Is Absent in CDlla -~-
Mice. Anti-LFA-1 mAb treatment during either priming (Fig. 9 ).
CD11a
-/-Mice Do Not Prime~Reject Injected Tumor Cells. W e tested the ability o f m u t a n t mice to reject a transplant w i t h i m m u n o g e n i c fibrosarcoma t u m o r cells ( M C 5 7 , H-2b). In n o r m a l mice, i n j e c t i o n o f these t u m o r cells into footpads induces lymphocytic infiltration of footpads and a visible swelling reaction by 6-9 d, followed by tumor clearance and normalization of footpad thickness within 14 d. CDlla mutant mice showed no swelling at 6-9 d, and developed massive tumor burdens by day 14 (Fig. 10) . Histologic analysis of LFA-1 expressing (Fig. 4 , B and C) (Fig. 10, D and  E) . We then immunized mice into footpads with the fibrosarcoma cell line MC57-gp (the same MC57 cell line as above transfected to express the major immunogenic epitope of the LCMV glycoprotein [30] ) to induce CD8 + CTL responses against LCMV in H-2 b mice (43). 7 d after injection of live MC57-gp into footpads, LCMV-gp-specific CD8 + CTL became detectable in spleens of CD11a +/-mice but not in CDlla -/-mice (Fig. 10 F) . Accordingly, CD11a +/-mice, but not CD11a -/-mice, cleared the MC57-gp tumor cells (data not shown).
Discussion
The role of adhesion molecules during the cellular immune response is multifaceted and involves functions asso- ciated with recirculation through the lymphatic network, interaction with and migration through endothelial lining o f blood vessels, cellular adhesion events important during antigen specific activation, and, finally, cell contact during T ceil effector functions (reviewed by Springer et al. [9] ). In vitro and in vivo findings suggest that LFA-1 is important in lymphocyte migration across the H E V into peripheral L N and Peyer's patches (22) . Thus it would be expected that immune reponses to peripheral antigens, where 1423 Schmits et al.
priming o f T cell responses occurrs in the draining lymph nodes, would be defective in LFA-l-deficient mice. W e used intravenous infection to assess C T L responses in m utant mice. Because i.v. infection results in a viremia and dissemination o f virions lymphocytes are likley to be primed in the spleen, circumventing the need for efficient lymphocyte recirculation through lymph nodes and migration across endothelial barriers. Nevertheless, in contrast to reports that LFA-1 is crucial for lymphocyte proliferation against virus-infected cells and CTL effector function (1, 18, 19) , ex vivo assays from LCMV-and VSV-infected CD11a -/-mutant mice revealed that LFA-1 deficient CTL had no defect in killing cell line-derived targets. These assays also suggested that antigen-specific CTL had undergone sufficient proliferation in vivo for normal killing responses ex vivo. The implication of these observations is that LFA-1--deficient T cells are capable of undergoing activation and proliferation with no discernable defect compared to normal mice. Reports that lymphocyte proliferation and CTL function is defective after anti-LFA-1 antibody treatment might be a characteristic of the in vitro nature of the assay, or might reflect non-specific effects of antibody treatment, such as capping of other crucial surface molecules or even killing of effector cells. On the other hand, T cells developing in LFA-l-deficient mice may have compensatory alterations in the expression of other molecules that may serve to mask the LFA-1 defect. Ex vivo CTL function using +/-or -/-CTL against targets derived from CD11a -/-mice suggested that CD 1 l a -/-effectors were no better at killing -/-targets than were effector cells that had developed in mice with normal levels ofLFA-1. IfT cell development in CD11a -/-mice had managed to compensate for LFA-1 deficiency, as evidenced by normal response in vivo to virus, it was not evident in a differential ability to kill -/-targets in vitro. If anything, +/-effectors appeared to be slightly better at killing -/-targets in this sensitive assay, which may reflect a slight outpefformance (proliferation and or killer function) ofT cells from LFA-l-expressing mice. It should be mentioned that mutant mice also have about twofold greater number of splenocytes than heterozygous mice, thus any minor defect in CTL responses to virus in mutants may be overcome by the sheer excess of T cells present.
Peritoneal lavage after thioglycollate treatment indicated that LFA-1 is not crucial but nevertheless important in extravasation of polymorphonuclear leukocytes and monocytes into the peritoneum in response to inflammatory stimulus. Observed decreases in infiltrate reflected an absolute reduction in cell numbers rather than a shift in the kinetics of the inflammatory response. This finding suggests a significant role for LFA-1 in neutrophil and monocyte responses to local infection.
DTH responses against DNFB were virtually absent in LFA-l-deficient mice. Moreover, immunization in the base of the taft with KLH or OVA in CFA or incomplete FA had little affect on the size of inguinal or paraortic LNs, whereas similar treatment on heterozygons mice resulted in marked lymphoadenopathy (data not shown). Both of these situations could be explained by a recirculation defect, but do not rule out a defect in priming. The lack of tumor rejection aider inoculation of MC57 fibrosarcoma cells into footpads and the failure of LCMVgp-transfected MC57 cells to prime ag-specific responses are also consistent with a recirculation defect in CD1 la -/-mice.
Although this is the first report that LFA-1 is crucial for priming immune responses against non-virus-induced syngeneic tumors, these results again do not determine if a defect in priming in draining peripheral LN accompanies a lymphocyte recirculation defect. However, our studies with LCMV and VSV infections suggests that priming is effcient in the absence of LFA-1, at least, as it appears, in the context of virus infections in the spleen. Differential priming requirements could reflect the involvement of different types of APC in the peripheral lymph nodes versus the spleen (24) . The importance of the strength of the activation signal in LFA-l-deficient cells is exemplified by our finding that proliferative responses of CD11a-/-lymphocytes was absent aRer treatment with soluble CD3 but relatively normal after treatment with cross-linked anti-CD3 mAb. Our in vitro findings that proliferation of CDlla -/-lymphocytes is significantly reduced contrasts with in vivo responses of CD1 la -/-mice to systemic virus infections. Taken together, our results suggest a differential requirement for LFA-1 for lymphocyte activation and proliferation depending, perhaps, on the type of APC involved in presenting antigen to T cells, or, on the microenvironment in which antigen presentation occurs. 
